Phase 2 Trial of Combination Radiotherapy and Pembrolizumab Plus Chemotherapy in Patients With Previously Untreated Metastatic NSCLC: NJLCG 1902
Adding radiotherapy to pembrolizumab plus platinum-doublet chemotherapy led to promising efficacy in patients with previously untreated metastatic NSCLC. Although caution should be exercised with regard to pneumonitis, adverse events were tolerable. Further research is needed to confirm the efficacy and safety of this strategy.
Authors
- Keiichi Jingu (ORCID: https://orcid.org/0000-0002-7032-1577)
- Aya Suzuki (ORCID: https://orcid.org/0000-0003-4962-3332)
- Hisashi Tanaka (ORCID: https://orcid.org/0000-0003-2009-0210)
- Eisaku Miyauchi (ORCID: https://orcid.org/0000-0002-6837-6392)
- Tomonori Makiguchi (ORCID: https://orcid.org/0000-0001-9249-7904)
- Hisatoshi Sugiura (ORCID: https://orcid.org/0000-0002-4335-7048)
- Hitomi Nogawa
- Taku Nakagawa (ORCID: https://orcid.org/0000-0002-4157-1112)
- Rei Umezawa (ORCID: https://orcid.org/0000-0002-7280-3676)
- Yosuke Horii
- Akira Anbai
- Hiroshi Yokouchi (ORCID: https://orcid.org/0000-0001-5964-0051)
- Akira Inoue (ORCID: https://orcid.org/0000-0002-5000-9084)
- Ryo Morita (ORCID: https://orcid.org/0000-0002-4746-3163)
- Yoko Tsukita (ORCID: https://orcid.org/0000-0003-3958-8641)
- Nozomu Kimura (ORCID: https://orcid.org/0009-0002-4596-0964)
Institutions
- Hirosaki University (JP)
- Iwate Medical University (JP)
- Tohoku University (JP)
- Miyagi Prefectural Hospital Organization (JP)
- Misasa Onsen Hospital (JP)
- Yamagata Prefectural Central Hospital (JP)
- Akita Industrial Technology Center (JP)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1016/j.jtocrr.2025.100817
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05